RE:RE:RE:NGM down 70% pre-marketSorry, I was not even aware NGM had an ocular drug. Ithought they were all about cancer after they exited NASH. Why would the stock get so torched on the ocular drug - have their cancer drugs also gone by the wayside in the last coouple of years? I just ahve not been paying much attention to NGM.
On safety, and really on every aspect of TH-1902, we only have a very selected and narrow group of data so far. We know that six patients taking one dose of TH-1902 did not have any real side-effects. That is pretty slim pickings on safety data. Of course, we do know one patient went many months ont he drug and reportedly could have gone longer had they wanted to, so that sounds very promising. And we have three responders in the phase 1a, none of which gave us proof of concept unfortunately. We also had a long period of time during the 1a when TH went very quiet - something was going on the and it likely was not positive or we would have heard about it. Clearly there were some safety issues at the 420mg dosing level during that quiet period and they have divulged some sfety info about that. But we have bever gotten a full readout of the phase 1a and have been told that will come early in 2023. I suspect we will then ehar a lot more about whatever happened around the 420mg dosing level.
One thing I have considered is that full phase 1a readout will have more concerning info in it, so they just cherry picked the good stuff to share with us until that comes out. The hope might be to get a good piece of news on the phase 1b by the end of this year, do a stock offering quickly after that and get that all wrapped up before the full readout on the 1a comes out.
Wino115 wrote: Accept the point, but important to note the NGM drug was for a rare ocular disease and it was not a similar type of construct or approach to an oncology PDC or even ADC. Just don't want folks here to look at that as a direct analogy around PDCs as opposed to the general biotech trial analogy that it is.
I still like the fact that we appear to have safety issues within normal boundaries for an oncology trial and the active ingredient is well known and generic --we just need to get proof the delivery system is working, effective, and the reason it's helping the target population where others have failed.
Biobob wrote: Well it works both way... Th1902 had maybe 25% downside in the price atm and 100%+ upside in the shorterm and 10 bagger potential in the medium term.. and we shall see once where there in the long term...